Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis
GlobalData has released its new PharmaPoint Drug Evaluation report, Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lillys anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZs SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.
AB Science is developing a novel oral c-Kit inhibitor (tyrosine kinase inhibitor) known as masitinib, or AB101. Inhibition of the c-Kit pathway leads to a decrease in histamine levels, mast cells, and IL-4 production, thus decreasing the allergic response. This antineoplastic drug is currently in an international, multicenter, randomized, double-blind, placebo-controlled, three-parallel group Phase IIb/III clinical trial for RA in the US and Czech Republic.
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Masitinib including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Masitinib for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Masitinib performance
- Obtain sales forecast for Masitinib from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)